Read by QxMD icon Read

Cancer Biotherapy & Radiopharmaceuticals

Kevin J H Allen, Rubin Jiao, Mackenzie E Malo, Ekaterina Dadachova
Radioimmunotherapy offers an effective way to direct ionizing radiation to cancer cells through attachment of radionuclides to antibodies while limiting negative effects of off-target irradiation. This, however, requires effective facile methods for attachment of therapeutic radionuclides onto antibodies. Herein, the authors report their efforts in evaluating N-succinimidyl S-acetylthioacetate (SATA), a commercially available reagent, for use as a bifunctional chelating agent (BCA) to attach 188 Rhenium (188 Re) onto h8C3, a humanized IgG antibody that can effectively target extracellular melanin present in malignant melanoma...
July 16, 2018: Cancer Biotherapy & Radiopharmaceuticals
Shin Hye Ahn, Eszter Boros
New, targeted imaging tracers enable improved diagnosis, staging, and planning of treatment of disease and represent an important step toward personalized medicine applications. The combination of radioisotopes for nuclear imaging with fluorophores for fluorescence imaging provides the possibility to noninvasively assess disease burden in a patient using positron emission tomography/single-photon emission computed tomography, followed by fluorescence imaging-assisted surgical intervention in close succession...
July 13, 2018: Cancer Biotherapy & Radiopharmaceuticals
Bo Xu, Jia Liu, Xin Xiang, Shunhai Liu, Pingyong Zhong, Fei Xie, Tinggang Mou, Liang Lai
OBJECTIVE: To analyze the expression of micro-RNA 143 (miRNA-143) in the patients with pancreatic cancer and to explore the influence of overexpression of miRNA-143 on pancreatic cancer cells. METHODS: Twenty-five patients with pancreatic cancer that received treatment in their hospital were included in this study. Pancreatic cancer tissues of the patients were surgically removed, and cancer-adjacent tissues were taken for control. Semiquantitative reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expressions of miRNA-143 and its target gene Kirsten rat sarcoma (KRAS) in pancreatic cancer tissues and cancer-adjacent tissues...
July 13, 2018: Cancer Biotherapy & Radiopharmaceuticals
Milad Sabzevary-Ghahfarokhi, Hedayatollah Shirzad, Mahmoud Rafieian-Kopaei, Mahdi Ghatreh-Samani, Mojtaba Shohan
Secreted inflammatory cytokines are considered as critical mediators in the tumor microenvironment. Cancer cells play a significant role in the differentiation of effector T cells to exhausted T cells through mediator production. Effector T cells that undergo tumor microenvironment become terminally differentiated into exhausted T cells. These changes create an opportunity for tumorigenesis and invasion of cancer cells. Despite having some characteristics of effector T cells, the exhausted T cells lose their antitumor properties...
July 13, 2018: Cancer Biotherapy & Radiopharmaceuticals
Aixia Sun, Xiaolan Tang, Dahong Nie, Yixiang Fan, Ganghua Tang
OBJECTIVES: As acid-base imbalance is involved in many pathological processes, the capability to image tissue pH alterations in the clinic could offer new ways to detect disease and respond to treatment. In this study, the authors show that tissue pH can be imaged in vivo with 11 C-labeled bicarbonate (H11 CO3 - ) buffer and positron emission tomography (PET). METHODS: H11 CO3 - was produced by on-column NaOH adsorption. Biodistribution of H11 CO3 - in normal mice was determined...
July 13, 2018: Cancer Biotherapy & Radiopharmaceuticals
Yiqi Deng, Feng Zhao, Zhenhua Zhang, Fujie Sun, Mingxing Wang
The long noncoding RNA (LncRNA) SNHG7 (small nuclear RNA host gene 7) is a novel LncRNA and functions as an oncogene to promote tumor proliferation and inhibits apoptosis in many cancers. However, the role of SNHG7 in osteosarcoma (OS) remains to be further investigated. In this study, OS tissues and corresponding relative normal tissues (n = 30) were collected to determine the expression of SNHG7 in OS. The results indicated that high SNHG7 level in OS correlated with high Enneking stage, distant metastasis, and short overall survival time of OS patients...
July 10, 2018: Cancer Biotherapy & Radiopharmaceuticals
Murali Kesavan, J Harvey Turner, Danielle Meyrick, Sharon Yeo, Giuseppe Cardaci, Nat P Lenzo
Prostate-specific membrane antigen (PSMA)-based radiopeptide/radioligand therapy represents a rapidly expanding field in the management of metastatic castrate-resistant prostate cancer (mCRPC). However, there remains concern for the development of significant toxicities in heavily pretreated patients. In this study, the authors present their local experience, with respect to efficacy and toxicity, of 22 consecutive patients treated with lutetium-177-DOTAGA-(I-y)fk(Sub-KuE) or 177 Lu-PSMA I&T radioimmunotherapy for progressive mCRPC, followed up over 1 year...
July 10, 2018: Cancer Biotherapy & Radiopharmaceuticals
Zhang Jinshan, Li Yuan, Wen Ge, Deng Yongmei, Yao Hongxia
Angiolymphoid hyperplasia with eosinophilia (ALHE) is a distinctive benign vascular disease that can be challenging to treat due to inconsistent results for various treatment modalities. The authors present a case of ALHE on the right auricle of a 54-year-old Chinese woman who underwent brachytherapy using 32 P simple-drug membranes and had a promising outcome over 8 years of follow-up. This case indicated that 32 P brachytherapy may represent a novel ALHE treatment method that produces a favorable long-term outcome...
June 29, 2018: Cancer Biotherapy & Radiopharmaceuticals
Wenjing Yu, Yuancai Xiang, Guosong Luo, Xiaofang Zhao, Bin Xiao, Ying Cheng, Chunhong Feng, Chunyan Duan, Xianming Xia, Vincent Kam Wai Wong, Rongyang Dai
Cholangiocarcinoma (CCA) is a highly malignant and aggressive tumor of the bile duct that arises from epithelial cells. Chemotherapy is an important treatment strategy for CCA patients, but its efficacy remains limited due to drug resistance. Salubrinal, an inhibitor of eukaryotic translation initiation factor 2 alpha (eIF2α), has been reported to affect antitumor activities in cancer chemotherapy. In this study, the authors investigated the effect of salubrinal on the chemosensitivity of doxorubicin in CCA cells...
June 29, 2018: Cancer Biotherapy & Radiopharmaceuticals
Mine Araz, Derya Cayir, Bekir Ucan, Alper Dilli, Erman Çakal
OBJECTIVE: (1)To define a quantitative cutoff value for incidental pituitary Technetium-99m methoxyisobutylisonitrile (Tc-99m MIBI) uptake above which is of clinical importance and (2) to investigate possible factors affecting the intensity of uptake in pituitary adenoma. MATERIALS AND METHODS: A retrospective analysis of 55 patients with a simultaneous parathyroid single-photon emission computed tomography and pituitary magnetic resonance imaging were included...
June 20, 2018: Cancer Biotherapy & Radiopharmaceuticals
Mohamed H Aboumanei, Aly A Abdelbary, Ismail T Ibrahim, Mina I Tadros, Mohamed T El-Kolaly
Recently, the direct intratumoral (i.t.) injection of anticancer agents has been investigated. A newly synthesized Antineoplaston A10 analog 3-(4-methoxybenzoylamino)-2,6-piperidinedione (MPD) showed an antitumor activity in human breast cancer cell line. Unfortunately, MPD suffered from poor water solubility. Pseudoternary phase diagram of oil (isopropyl myristate), surfactant (Tween 80), cosurfactant (ethanol), and water was plotted. MPD microemulsion (MPDME) was developed and characterized for particle size (PS), polydispersity index (PDI), zeta potential (ZP), and morphology (transmission electron microscopy)...
June 12, 2018: Cancer Biotherapy & Radiopharmaceuticals
Nikki A Thiele, Justin J Wilson
The α-emitting radionuclide actinium-225 possesses nuclear properties that are highly promising for use in targeted α therapy (TAT), a therapeutic strategy that employs α particle emissions to destroy tumors. A key factor, however, that may hinder the clinical use of actinium-225 is the poor understanding of its coordination chemistry, which creates challenges for the development of suitable chelation strategies for this ion. In this article, we provide an overview of the known chemistry of actinium and a summary of the chelating agents that have been explored for use in actinium-225-based TAT...
June 11, 2018: Cancer Biotherapy & Radiopharmaceuticals
Yongxin Lin, Shan Liu, Le Su, Qiao Su, Juze Lin, Xuhui Huang, Changjun Wang
Hepatocellular carcinoma (HCC) is one common malignancy. The authors previously demonstrated that miR-570 regulates the development of HCC. This study detected the effect of miR-570 on cell apoptosis, angiogenesis, T cell activation, and proliferation in a tumorigenicity assay in nude mice. miR-570 mimics and negative control (NC) were transfected into SMMC7721 cells, and then, the cells were subcutaneously injected in the right flank in nude mice. Six weeks later, the dissected tumors and peripheral blood were collected...
June 6, 2018: Cancer Biotherapy & Radiopharmaceuticals
Roland O Saahene, Jianjie Wang, Mo-Lin Wang, Elvis Agbo, Dezhi Pang
Paeonol, a phenolic component from the root bark of Paeonia moutan, has been identified to possess antitumor effects. However, the effect of paeonol and the mechanism of CXCL4/CXCR3-B signals in paeonol-induced breast cancer cell remain unknown. After MDA-MB-231 cells were pretreated with paeonol or DMSO, the proliferation activity was detected by MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide), Hoechst, Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL), and Annexin-V/propidium iodide staining flow cytometry...
May 30, 2018: Cancer Biotherapy & Radiopharmaceuticals
Diane E Milenic, Young-Seung Kim, Kwamena E Baidoo, Karen J Wong, Rachel Barkley, Jose Delgado, Martin W Brechbiel
Refinement of treatment regimens enlisting targeted α-radiation therapy (TAT) is an ongoing effort. Among the variables to consider are the target molecule, radionuclide, dosage, and administration route. The panitumumab F(ab')2 fragment targeting epidermal growth factor receptor tolerated modification with the TCMC chelate as well as radiolabeling with 203 Pb or 212 Pb. Good specific activity was attained when the immunoconjugate was labeled with 212 Pb (9.6 ± 1.4 mCi/mg). Targeting of LS-174T tumor xenografts with the 203 Pb-panitumumab F(ab')2 demonstrated comparable amounts of uptake to the similarly radiolabeled panitumumab IgG...
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Yongbo Song, Chao Song, Sixing Yang
MiR-30d-5p, a member of the microRNA family, was recently reported to regulate androgen receptor signaling in prostate cancer (PCa). Ecto-5'-nucleotidase (NT5E/CD73) is a pivotal regulator of tumor migration and has angiogenetic properties. However, the undiscovered function of miR-30d-5p and whether it targeted NT5E in PCa remain uncertain. In this study, the authors observed miR-30d-5p was significantly downregulated in PCa tissues and cell lines compared with the adjacent normal tissues and normal prostate cells, respectively...
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Martin W Brechbiel
No abstract text is available yet for this article.
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Baoyong Wang, Hongwei Chen, Chunfen Zhang, Tian Yang, Qiaofei Zhao, Yifan Yan, Yu Zhang, Feng Xu
Primary hepatocellular carcinoma (HCC) is one of the most common malignant tumors. At present, the molecular mechanism of HCC remains unclear. A recent circular RNA (circRNA) profiling study showed that circRBM23 expression was upregulated in HCC tissues. Therefore, in this study, the impact of circRBM23 during the progression of HCC was evaluated. The expression levels of circRBM23 and miR-138 in HCC tissues and HCC cell lines were determined by RT-PCR and the results indicated that circRBM23 expression was increased in the HCC tissues and HCC cell lines, whereas miR-138 expression was decreased...
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Wei Lu, Peng Du, Chao Yang, Fuqiang Jiang, Peng Xie, Jian Yang, Zhe Zhang, Junpeng Ma
BACKGROUND AND AIM: Pain is a prevalent and serious problem in patients with cancer. This study aimed to investigate the clinical value of the implantation of radioactive particle 125 I in treating cancer and its pain. MATERIALS AND METHODS: From February 2014 to February 2015, 38 patients with malignant tumor received computed tomography (CT)-guided 125 I radioactive particle implantation to treat cancer pain in this hospital. Before surgery, the lesions were calculated by brachytherapy treatment planning system (TPS) to get the local number of particles that are required for implantation...
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Naipeng Cui, Jianhong Shi, Chuanwei Yang
Resistance to therapies and disease recurrences after surgery or treatment are common challenges in breast cancer management in clinic. Active immunotherapy using human epidermal growth factor receptor 2 (HER2)-targeted vaccines represents an attractive option in combating breast cancer. Different HER2-derived vaccines have been developed over the years. Many clinical trials have been carried out in evaluating HER2-based vaccines. The authors reviewed current literature on HER2-based vaccines in clinical trials...
June 2018: Cancer Biotherapy & Radiopharmaceuticals
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"